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Abstract 
Background: There is debate regarding optimum management of ovarian immature teratomas 
(IT).  In adult women, postoperative chemotherapy is standard, except for Stage I, grade 1 
disease, whereas surgery alone is standard in pediatric patients. To determine the role of 
chemotherapy, we conducted a pooled analysis of pediatric and adult clinical trials. 
Methods:  Data from seven pediatric and two adult trials were merged in the Malignant Germ 
Cell Tumor International Collaborative dataset.  Four trials included patients with newly 
diagnosed pure ovarian IT and were selected for this analysis (INT 0106, GC2, GOG 0078 and 
0090). Patients treated on adult and pediatric trials were analyzed separately. The primary 
outcome measures were event-free (EFS) and overall survival (OS).  
Results: Ninety eight pediatric and 81 adult patients were included. In the pediatric cohort, 
ninety patients were treated with surgery alone whereas all adult patients received postoperative 
chemotherapy. The 5 year EFS and OS were 91% and 99% in pediatric cohort compared with 
87% and 93% in adults. There were no relapses in grade 1 patients, irrespective of stage or age. 
Only one adult patient with grade 2 IT relapsed. Among grade 3 patients, stage was significantly 
associated with relapse. Administration of chemotherapy did not decrease relapse risk in 
pediatric cohort.   
Conclusion: Grade is the most important risk factor for relapse in ovarian IT. There were no 
relapses in grade 1 patients, irrespective of age or stage. Adjuvant chemotherapy did not decrease 
relapse risk in pediatric cohort, and its role in adults remains unresolved.  
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Introduction
 
Immature teratomas (IT) of the ovary represent about 1% of ovarian tumors. IT are composed of 
tissues derived from all three embryonic layers, namely mesoderm, endoderm and ectoderm, and 
are graded based on the proportion of tissue containing immature neural elements. The grade and 
stage of these tumors have been shown to be of prognostic significance and are therefore used to 
make therapeutic decisions.
1, 2
  
       There is no consensus on the management of patients with ovarian IT. Significant 
differences exist between pediatric and adult groups about the necessity and utility of 
chemotherapy for patients with higher grade and stage disease. Therapeutic recommendations in 
adult women are based on two seminal studies. In 1976, Norris et al performed a retrospective 
analysis of 58 patients, and observed an 18% recurrence rate in grade 2 tumors and 70% 
recurrence in grade 3 tumors, resulting in the recommendation to use chemotherapy for grade 2 
and 3 tumors
3
. Gershenson et al reported outcomes of 41 patients with Stage I-IV
 
ovarian IT and 
observed recurrences in 94% of patients treated with surgery alone compared with 14% in 
patients treated with surgery and chemotherapy
4
. Henceforth, the standard of care for adult 
women with ovarian IT has been postoperative chemotherapy for all patients except Stage I, 
grade 1 tumors.       
       Clinical practice in children has been led by evidence provided by a pediatric intergroup trial 
INT 0106 conducted in the US. Patients with completely resected ovarian IT were observed 
closely without postoperative chemotherapy
5, 6
.  Forty-four patients with completely resected 
ovarian IT were enrolled; 31 patients had pure IT with tumor grade 1 (n=17), 2 (n=12) or 3 
(n=2). Thirteen patients had foci of yolk sac tumor (YST). Gliomatosis peritonei (GP) was 
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present in 27% of patients and three of the sixteen patients with lymph node sampling had nodal 
gliomatosis. At four years, the event-free survival (EFS) was 97.7% with an overall survival 
(OS) of 100%. This study concluded that surgery alone is curative for children with completely 
resected ovarian IT, regardless of grade or presence of microscopic foci of YST
5
. A similar study 
conducted in the UK followed 124 patients with IT (54 ovarian) after surgical resection. Eleven 
patients had GP and six patients had nodal gliomatosis. The EFS and OS was 85.9% and 95.1%, 
respectively and the authors concluded that treatment of ovarian IT is primarily surgical
7
.  
       To highlight these differences and gain clarity on the role of postoperative chemotherapy in 
the management of pure IT of the ovary, we conducted a pooled analysis. The Children’s 
Oncology Group (COG) and the Children’s Cancer and Leukemia Group (CCLG) agreed to 
merge 25 years of clinical trial data on pediatric germ cell tumors (GCT) to form the Malignant 
Germ Cell International Collaborative (MaGIC). Subsequently data from the Gynecologic 
Oncology Group (GOG) germ cell tumor clinical trials were added.  This report presents our 
analysis of pediatric and adult patients with ovarian IT. We compare these two groups and 
identify similarities and differences, with the goal of establishing a uniform treatment approach 
across all age groups. Data from some of these trials have been previously published as separate 
reports
5, 7, 8
.   
Methods 
After signing a memorandum of understanding, which specified the variables to be included and 
how data were to be de-identified, patient data from seven GCT clinical trials conducted by COG 
or CCLG between 1983 and 2009 were included in the MaGIC dataset. Data from two GOG 
clinical trials were added subsequently. Four of the nine trials included patients with IT. These 
were INT 0106 (COG), GC 2 (CCLG), GOG 0078 and GOG 0090.  Each study had different 
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eligibility criteria for inclusion of IT patients. The INT 0106 study included patients upto 21 
years of age with biopsy proven IT, Stages I and II, grades 1-3. Presence of GP within the 
abdomen or pelvis did not result in upstaging in this study. The GC2 study included patients 
younger than 16 years with biopsy proven IT, all stages and grades. The pediatric studies 
included IT at all sites in both genders. The GOG 0078 study included patients with IT, Stage I, 
grades 2 and 3, completely resected Stage II and III, all grades. The GOG 0090 protocol included 
patients with incompletely resected Stage II, III and IV, grades 1-3. Each trial had received 
research ethics board approval from the relevant agencies. This project was approved by the 
Dana-Farber/Harvard Cancer Center Institutional Review Board. 
      From the larger dataset, we selected only females with newly diagnosed, pure IT of the 
ovary. Patients with mixed malignant GCT of the ovary and patients with extra gonadal IT were 
excluded. Patient characteristics that were included in the dataset were age at diagnosis, 
histology, tumor markers, stage, grade, whether adjuvant chemotherapy was administered, and 
clinical outcome.    
Staging 
Patients treated on GOG protocols were staged using the FIGO staging
9
, whereas pediatric 
patients were staged using the COG or CCLG staging systems
5, 7
. Due to irreconcilable 
differences in staging between these systems, adult and pediatric patients were analyzed 
separately. A few adolescents were treated on GOG protocols. They were analyzed with the adult 
cohort as they were staged and managed following the adult treatment algorithm. Within the 
pediatric staging systems, a major difference between the COG and the CCLG systems was that 
the presence of GP in the COG system did not result in upstaging of Stage I patients, whereas in 
the CCLG system, patients with GP were classified as Stage 3. To resolve this discrepancy, we 
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retrospectively applied the CCLG staging to COG patients, so that all patients with GP were 
defined as Stage III disease. 
Grading 
All tumors required central pathology review at the time of enrollment by the respective 
cooperative group pathologist to confirm histology and were graded according to the criteria by 
Norris et al.
3
 and Robboy and Scully
10
. Grade 1 was defined as immature tissue present in <1 
low power field (LPF) (x 4) /slide, grade 2 as immature tissue 1-3 LPF/slide and grade 3 as >3 
LPF/slide.  
Tumor markers 
Serum alpha-fetoprotein (AFP) levels were available for most patients, and they were classified 
as being normal if <10 ng/ml, and elevated if ≥10 ng/ml. Patients with AFP >1000 ng/ml were 
excluded, as this level of AFP elevation was considered more likely to indicate malignant GCT 
elements, warranting more aggressive treatment
11
. 
Treatment 
Complete surgical excision at diagnosis was undertaken when feasible. In the pediatric trials 
(INT 0106 and GC2), chemotherapy was not recommended after surgery. However, some 
patients did receive chemotherapy immediately after surgery at the discretion of the treating 
physician. In the GOG trials (GOG 0078 and GOG 0090), chemotherapy was administered 
postoperatively for all patients.  
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Statistical analysis 
The primary outcomes were event-free survival (EFS) and overall survival (OS). EFS was 
defined as the time interval from date of diagnosis to relapse or progression, second malignancy, 
death, or date last seen (whichever occurred first). Patients who experienced a relapse, 
progression or second malignancy were considered to have experienced an event; otherwise the 
patient was censored at last contact. OS was defined as the time interval from date of diagnosis 
to death or date last seen (whichever occurred first). Patients who died, regardless of cause were 
considered to have experienced an event; otherwise the patient was censored at last contact.  
The effects of various factors  including age at diagnosis, stage, grade, tumor marker levels, and 
treatment received on risk for EFS-event or death were estimated using relative risk regression
13
. 
We constructed survival curves using the Kaplan-Meier method 
12
.  Ninety-five percent 
confidence intervals for the Kaplan-Meier estimates at specified time points were calculated by 
using the complementary log-log transformation.
13
  The two-sided log-rank test to compare EFS 
across groups defined by the risk factors
13
 was used to assess the prognostic significance of the 
characteristics with P-values <0.05 considered significant. 
For adult patients, a backwards stepwise procedure was used to identify factors that were 
significantly associated with risk for an EFS-event. A selection probability of 0.05 was used to 
retain factors in the model. Because of issues with colinearity of predictor variables, only stage 
and grade could be entered into the starting model for the selection process. All analyses were 
conducted using Stata version 13.1 (College Station, TX).   
 
 
 
8 
 
 
Results 
A total of 193 patients with pure ovarian IT were identified from the four clinical trials. Six 
pediatric patients were excluded as they had mixed malignant GCT on central review. Eight 
adult patients were excluded; seven patients had recurrent IT at time of enrollment and one 
patient had mixed malignant histology on central review. One hundred and seventy nine patients 
with pure IT were included in the final analysis; 98 patients were treated on the pediatric trials 
and 81 patients treated on adult GOG trials.  
Characteristics, Treatment and Outcome of Pediatric Patients 
       Characteristics of the pediatric patients are presented in Table 1. The mean age at 
presentation was 10 years (range 0-17 years). Sixty percent of patients had Stage I disease. The 
mean AFP was 83 ± 182.7 ng/ml. Ninety of the 98 patients were treated with surgery alone and 
eight patients received postoperative chemotherapy. Median follow up was 6.8 years (range 1.7-
14 years)  
         Nine of the 98 patients relapsed, with a 5-year EFS and OS of 0.91 (0.84-0.95) and 0.99 
(0.93-1.00) respectively.  As shown in Table 2, there were no relapses in patients with grade 1 or 
grade 2 tumors, irrespective of stage. Among patients with grade 3 tumors, 8/38 patients (21%) 
relapsed. Stratifying grade 3 tumors by stage (Fig 1), the estimated 5-year EFS for patients with 
grade 3, Stage I and II disease was 0.92 (0.72-0.98), compared with 0.52 (0.22-0.75) for grade 3, 
Stage III patients (p= 0.005). The OS for all grade 3 patients, irrespective of stage was 100 
percent. Neither age at diagnosis nor AFP level was related significantly to the risk of relapse. 
Administration of postoperative chemotherapy did not decrease the risk of relapse in the 
pediatric cohort.   
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     Table 3 outlines the clinical characteristics of the nine pediatric patients who relapsed. All but 
one of the nine patients were salvaged, three with surgery alone. 
Characteristics, Treatment and Outcome of Adult Patients 
Characteristics of the 81 adult patients are outlined in Table 4. Fifty-six percent of patients had 
grade 3 disease, compared with 39% in the pediatric cohort. Additionally, 7% of adult patients, 
but no pediatric patients, had Stage IV disease. The mean AFP was 63.17 ± 155.18 ng/ml. All 
patients, regardless of stage, were treated with chemotherapy after surgery. Median follow up 
was 12 years (range 0.3 -21.9 years) 
     Eleven of the 81 patients relapsed, with an estimated 5-year EFS and OS of 0.87 (0.77-0.93). 
and 0.93 (0.85-0.97) respectively. There were no relapses in patients with grade 1 tumors, 
irrespective of tumor stage. Among patients with grade 2 tumors, only 1 of 27 patients (3.7%) 
relapsed; this patient had Stage IIIc disease. Among patients with grade 3 tumors, 9 of 45 
patients (20%) experienced a relapse. Stratifying grade 3 disease by stage, the estimated 5-year 
EFS for patients with grade 3, Stage I and II disease was 0.91 (0.69-0.98) compared with 0.65 
(0.39-0.83) for grade 3, Stage III and IV disease (p = 0.01). The estimated 5-year OS for grade 3, 
Stage I and II disease was 0.91 (0.68-0.98) compared with 0.88 (0.61-0.97) for grade 3, Stage III 
and IV disease (p = 0.41) (Fig 2). Stepwise selection identified grade and stage as significantly 
associated with risk of relapse (Table 5). Age at diagnosis and AFP level were not significant 
risk factors for relapse.  
       As all the adult patients received postoperative chemotherapy, the effect of surgery versus 
chemotherapy could not be assessed. Table 6 shows the clinical characteristics of the patients 
who relapsed. Six of the eleven patients died.   
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Discussion 
This combined analysis was done in an attempt to simultaneously compare pediatric and adult 
patients with ovarian IT, to identify common risk factors and compare outcomes in two cohorts 
with different treatment strategies. Our analysis shows several striking similarities in the two 
groups, both in risk factors and in overall outcomes, despite differences in treatment. Risk factor 
analysis shows that for ovarian IT, grade is the most important risk factor for relapse across all 
age groups. In patients with grade 1 tumors there were no relapses, irrespective of stage. Among 
the 47 pediatric and adult patients with grade 2 tumors there was only a single relapse. This was 
an adult patient with Stage IIIc disease. The majority of relapses occurred in patients with grade 
3 tumors.  Twenty percent of patients (17/83) with grade 3 tumors relapsed, 21% in the pediatric 
cohort compared with 20% in the adult cohort. For patients with grade 3 tumors the risk of 
relapse differed by stage at presentation. Grade 3 patients with Stage I and II disease had an 
excellent EFS compared to Stage III and IV patients, in both the pediatric and adult cohorts.        
                 There were important differences in the treatment approach between the pediatric and 
adult cohorts in our study. Only eight of the 98 pediatric patients received chemotherapy, 
whereas all 81 adult patients received postoperative chemotherapy. Despite this, the 5-year EFS 
and OS were higher in the pediatric cohort compared with the adult cohort. This difference in 
outcome is likely to be a reflection of tumor grade, rather than treatment. Tumor grading varied 
by age, and grade 1 tumors were more frequent in the pediatric cohort compared with adults 
(31% vs. 9%), whereas grade 3 tumors were more common in the adult cohort (56% vs. 39%).  It 
is important to note that Stage I, grade 1 tumors were not enrolled the adult GOG studies. 
      Other studies have corroborated our results. Grade, stage and completeness of resection have 
been shown to be important risk factors for relapse
1,3,14
. In the study by Norris et al, the 
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recurrence rate was 70% in patients with grade 3 tumors and 18% in patients with grade 2 
tumors
3
. In a study by Gobel et al, including 116 patients with extracranial IT, 38 patients had 
incomplete resection. They found that immaturity in incompletely resected teratomas was a risk 
factor for relapse; there were no relapses in patients with completely resected IT, even amongst 
grade 3 tumors
14
.  Extent of resection was not available in our database, but adult patients were 
enrolled on two protocols, with eligibility based on stage and extent of resection. As inclusion 
criteria for these studies were based on extent of resection, we stratified patients with grade 3, 
Stage III by protocol, to determine if extent of resection influenced risk of relapse. The observed 
5-year EFS was 0.75 (0.13-0.96) for GOG0078 and 0.67(0.28-0.88) for GOG0090. As the 
numbers were so small (9 patients on GOG 0090 and 4 patients on GOG 0078), we did not 
perform the log rank test for this comparison.  It therefore appears that in patients with grade 3 
tumors, stage and lack of complete resection are associated with increased risk of relapse. 
       Similar to our study, other pediatric studies have shown no benefit of adjuvant 
chemotherapy postoperatively in the management of ovarian IT.  In a non-randomized study by 
Gobel et al, 76 patients were treated by surgery alone and 40 patients received adjuvant 
chemotherapy. There was no reduction in the number of subsequent relapses in the IT group 
receiving chemotherapy. However, risk factors were not balanced between the two treatment 
groups in this study
14
. 
     In contrast to the pediatric data, chemotherapy has been used for all adult patients with pure 
ovarian IT except those with Stage I, grade 1 tumors 
3, 4
. Vicus et al, reported on 34 women with 
ovarian IT, 32 of whom were Stage I, one was Stage IIB, and one was Stage IIIA. Three out of 
32 patients with Stage I disease recurred, all of whom had grade 2 or 3 disease. Consequently 
they recommended surveillance only for Stage I, grade I tumors and chemotherapy for Stage I, 
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grade 2 or 3 tumors
15
. Recently, several studies in adults have questioned the role of 
chemotherapy for IT. A multicenter Italian trial (MITO-9) reported on 28 patients with Stage I 
disease. Nineteen patients were treated with surgery alone, and nine patients received adjuvant 
postoperative chemotherapy. Four out of nineteen patients treated with surgery alone and 2/19 
patients treated with adjuvant chemotherapy recurred.  At recurrence, all patients were salvaged. 
The authors concluded that all patients with Stage I ovarian IT, regardless of grade, may be 
treated with surgery alone, with chemotherapy reserved for recurrence
16
. A UK study by 
Patterson et al adopted a close surveillance program post surgery for all Stage IA ovarian GCT. 
Four of fifteen patients relapsed, and only one of these patients could not be salvaged. They 
recommended surveillance for all Stage IA IT, regardless of grade
17
. Bonazzi et al undertook a 
prospective trial of patients with pure ovarian IT. Surgery alone was recommended for patients 
with Stage I or II and grade 1 or 2 tumors. Twenty two patients were followed after surgery 
alone. Two patients relapsed after surgery alone, and were salvaged, leading to the conclusion 
that such patients may be treated with surgery alone
18
. In our adult cohort all patients received 
adjuvant chemotherapy and therefore we are unable to comment on its efficacy. However, the 
risk of relapse in the grade 3 patients was not different between the adult and pediatric cohorts 
(20% vs. 14%, respectively), despite major differences in management. 
   Our study has several limitations. It was a combined database analysis of patients treated on 
multiple studies; hence, there were missing data and different staging systems were used. 
Although a small number of pediatric patients and most adults were treated with chemotherapy, 
there was no explicit documentation of objective response to chemotherapy. In addition clinical 
details at relapse were missing for adult patients, including pathologic information and treatment 
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at relapse. Despite these limitations, several important clinical messages may be drawn from our 
data.    
    In conclusion, our study shows that for all patients with ovarian IT, grade is the most 
important risk factor for relapse. In patients with grade 1 tumors, no patients relapsed in the 
pediatric or adult population, and in grade 2 tumors, only 2% of patients relapsed. We would 
thus advocate that for grade 1 and 2 tumors, surgery alone should be recommended for all stages 
across all age groups. In patients with grade 3 tumors, predominantly those with Stage III and IV 
disease, the risk of relapse remains. Adjuvant chemotherapy did not decrease the risk of relapse 
in the pediatric cohort. In the adult cohort, the role of chemotherapy for this group was not 
resolved in our study.  The ideal option would be to conduct a combined study of pediatric and 
adult patients with stage III-IV, grade 3 ovarian IT in an attempt to prospectively resolve this 
controversy, although the numbers needed to answer this question would be very large.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
References 
1. Gobel U, Calaminus G, Blohm M, et al. Extracranial non-testicular teratoma in childhood and 
adolescence: Introduction of a risk score for stratification of therapy. Klin Pediatr 209:228-234, 
1997 
2. Heifetz SA, Cushing B, Giller R, et al. Immature teratomas inchildren: Pathologic considerations. 
Am J Surg Pathol 22:1115-1124, 1998. 
3.  Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) teratoma of the ovary: a clinical and 
pathologic study of 58 cases. Cancer 1976;37:2359–72. 
4. Gershenson DM, del Junco G, Silva EG, Copeland LJ, Wharton JT, Rutledge FN. Immature 
teratoma of ovary. Obset Gynaecol 1986;68:624-9. 
5. Cushing B, Giller R, Ablin A, Cohen L, Cullen J, Hawkins E, et al. Surgical resection alone is 
effective treatment for ovarian immature teratoma in children and adolescents: a report of the 
pediatric oncology group and the children's cancer group. Am J Obstet Gynecol 1999;181:353–8 
6. Marina N, Cushing B, Giller R, et al. Complete surgical excision is effective treatment for 
children with immature teratomas with or without malignant elements: A Pediatric Oncology 
Group/Children’s Cancer Group Intergroup Study. J Clin Oncol 1999;17:2137-2143 
7. Mann JR, Gray ES, Thornton C, et al. Mature and Immature Extracranial Teratomas in children: 
The UK Children’s Cancer Study Group Experience. J Clin Oncol 2008; 26:3590-3597 
8. Williams S, Blessing JA, Liao SY, Ball Y. Adjuvant therapy of ovarian germ cell tumors with 
cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol 
1994;412;701-706. 
9. Odicino F, Pecorelli S, Zigliani L, Creasman WT. History of the FIGO cancer staging system. 
International J of Gynecol and Obstet 2008;101:205-210 
10. Robboy SJ, Scully RE. Ovarian teratoma with glial implants on the peritoneum. Hum Pathol 
1970;1:643-653.  
11. Murray MJ, Nicholson JC. α-Fetoprotein. Arch Dis Child Educ Pract Ed 2001;96:141-7 
12. Kaplan EL and Meier P. Nonparametric estimation from incomplete observations. J Amer Statist 
Assoc 53: 457-481, 1958. 
13. Kalbfleisch JD and Prentice RL. The statistical analysis of failure time data. John Wiley and 
Sons, New York, 2002 
14. Gobel U, Calaminus G, Engert J, et al. Teratomas in Infancy and Childhood. Med and Pediatr 
Oncol 1198;31:8-15. 
15. Vicus D, Beiner ME, Clarke B, Klachook S, Le LW, Laframboise S, Mackay H. Ovarian 
immature teratoma: treatment and outcome in a single institutional cohort Gynecol Oncol. 2011 
Oct; 123(1):50-3. 
16. Mangili G, Scarfone G, Gadducci A, Sigismondi C, Ferrandina G, Scibilia G, Viganò R, Tateo S, 
Villa A, Lorusso D. Is adjuvant chemotherapy indicated in stage I pure immature ovarian 
teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). Gynecol Oncol. 2010 
119(1):48-52. 
17. Patterson DM, Murugaesu N, Holden L, Seckl MJ, Rustin GJ. A review of the close surveillance 
policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer 
2008;18:43–50. 
18. Bonazzi C, Peccatori F, Colombo N, Lucchini V, Cantù MG, Mangioni C. Pure ovarian immature 
teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients. 
Obstet Gynecol 1994;84:598–604 
 
15 
 
 
 
 
 
Table1: Characteristics of Pediatric Patients Treated in Children’s Oncology Group (USA) and Children’s 
Cancer and Leukemia Group (UK) (n =98) 
 
Patient Characteristics Number (percentage) 
Mean ± SD 
Mean Age in years (Range) 10 ± 3 (0-17) 
Stage  I 
           II  
           III 
           IV 
59 (60%) 
12 (12%) 
27 (28%) 
0 
Grade  1 
            2 
            3 
           Missing  
30 (31%) 
20 (20%) 
38 (398%) 
10 (10%) 
AFP at Presentation (ng/ml) 
            Mean ± SD 
            Normal (<10) 
            High  
            Missing  
 
83 ± 182.7 
45 (46%) 
44 (45%) 
9 (9%) 
Treatment 
            Surgery + Chemotherapy 
            Surgery 
 
 
8 (8%) 
90 (92%) 
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Table 2: Univariate Analysis of Risk Factors for Relapse in Pediatric Patients with Ovarian Immature 
Teratoma (n=98)  
 
Patient 
Characteristics 
Level Number of 
Events 
/Number of 
patients 
Estimated  
Hazard Ratio 
(HR) (95% CI) 
p-Value
†
  
Age ≥11 years of 
age 
       7/ 49 3.76 (0.78-
18.10)  
0.076 
 
< 11 years of 
age 
      2/ 49 - 
Stage   
            
 
III       7/ 27 10.32 (2.14-
49.68) 
0.0003 
 
I-II      2/ 71 - 
Grade   
 
3      8/ 38 --* 
 
0.0006 
1-2      0 / 50 - 
AFP at 
Presentation 
  
High        5/ 44 1. 78 (0.43-
7.44) 
0. 42 
 
Normal       3/ 45 - 
Treatment 
             
             
Chemotherapy       3/ 8  6.61 (1.65-
26.45) 
0.002 
 
Surgery        6/ 90 - 
     *cannot estimate, grade 1-2 has no event, 
†
 p-value from the log rank test 
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Figure 1: Event Free Survival for Pediatric Patients with Ovarian Grade 3 Immature Teratoma, by  
Stage  
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Table 4: Characteristics of the 81 Patients Treated by the Gynecologic Oncology Group (USA) 
(n=81) 
 
Patient Characteristics Number (percentage) 
Mean ± SD 
Mean Age in years (Range)  26 ± 8.90  
 (11- 49) 
Stage  I 
           II  
           III 
           IV 
43 (53%) 
5 (6%) 
27 (33%) 
6 (7%) 
 
Grade  1 
            2 
            3 
           Missing  
7 (9%) 
27 (33%) 
45 (56%) 
2 (2%) 
AFP at Presentation (ng/ml) 
            Mean ± SD 
            Normal (<10) 
            High  
            Missing  
 
63.2 ± 155.18 
27 (33%) 
12 (15%) 
42 (52%) 
Treatment 
            Surgery + Chemotherapy 
            Surgery Alone 
 
 
81 (100%) 
0 (0%) 
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Figure 2: Event Free and Overall Survival for Adult Patients with Ovarian Grade 3 Immature Teratoma, 
by Stage 
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Table 5: Multivariate analysis of Risk Factors for Relapse in Adult Patients with Ovarian IT (n =79) 
Patient 
Characteristics 
Level Number of 
Events / 
Number of 
patients 
Estimated Hazard Ratio 
(95% CI) 
p-Value
††
  
Stage   
            
 
IV        2/ 5 6.02 (0.84-43.20)  
0.024 
 
III        6/ 27 6.76 (1.36-33.67) 
I-II        2/ 47 - 
Grade   
 
3        9/ 45 8.22 (1.01-67.13) 
 
 
0.014 
1-2       1/ 34 - 
        ††
p-value from the relative risk regression 
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Table 6: Characteristics of Adult Patients who Relapsed (N=11) 
Number Age (years) Stage Grade AFP (ng/ml) Outcome 
1 48  IVB 3 * Died 
2 38 III 3 * Alive 
3 47  IV * * Died 
4 23  IIIC 3 * Alive 
5 41  IA 3 63 Died 
6 20  III 3 * Alive 
7 21  IVA 3 * Alive 
8 37  IIC 3 4 Died 
9 13 III 3 * Died 
10 21  IIIC 3 * Died 
11 45 IIIC 2 * Alive 
* is missing values for Grade and AFP in database   
 
 
 
